Par Health Releases Financial Results for Q3 2025 and Offers Business Update

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 10 2025

0mins

Should l Buy ?

Source: Yahoo Finance

Company Overview: Par Health, Inc. has reported its financial results for Q3 2025 following its spin-off from Mallinckrodt plc, focusing on generic pharmaceuticals and sterile injectables, and highlighting a commitment to delivering essential medicines.
Financial Performance: The company achieved total net revenues of $337.1 million in Q3 2025, a 53.6% increase from the previous year, driven by growth in lidocaine patches and ADHD products, despite competitive pressures in opioid medications.
Pro Forma Results: On a pro forma basis, Par Health's combined net revenues for Q3 2025 were $388.5 million, reflecting a 5.3% decrease compared to the same period in 2024, with notable declines in sterile injectables revenue.
Future Outlook: Par Health plans to provide guidance for full-year 2026 in early 2026, focusing on optimizing operations and reducing leverage while addressing the demand for essential medicines.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free